US Markets
Home›US Markets›M&A & Deals›Global drugmakers pledge about $500 billion for expand…
Global drugmakers pledge about $500 billion for expanded U.S. capacity
The plan includes Pfizer’s $70 billion R&D and manufacturing deal with a three-year tariff grace period for its products.
Global drugmakers are expanding their U.S. presence with billions of dollars in pledged investment aimed at increasing manufacturing capacity and research, addressing supply chain risks, and reassuring investors, according to Reuters. Companies cited include Eli Lilly, Pfizer, AstraZeneca and Roche, which Reuters says have announced roughly $500 billion in U.S. investments. Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and it received a three-year grace period exempting its products from pharmaceutical-targeted tariffs. AstraZeneca is planning to invest $30 billion in U.S. research and development and supply chain infrastructure over five years. Eli Lilly said it planned at least $27 billion to build four U.S. plants and later outlined details for three plants in Alabama, Virginia and Texas. Lilly also plans additional U.S. manufacturing investment, including a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, and Reuters reports it expects to raise total U.S. investments by 25% to $55 billion over the next four years. The story also notes Roche’s plan to invest $50 billion in the U.S. over five years, plus a further $550 million investment to expand its Indianapolis diagnostics manufacturing hub.